IDH1 and glioma: DWI and PWI have also been used to assess the response of IDH1 mutant gliomas to pharmaceutical IDH mutant inhibitors, where an increase in the normalized rCBV and ADC were found to be a useful indicator of antitumor response within a timeframe of 2–4 months [242].